About the Bristol-Myers of Clopidogrel - Plavix
|
|
|
|
|
|
| About the manufactures of
Clopidogrel - Plavix |
Clopidogrel is a potent oral antiplatelet agent often used in the
treatment of coronary artery disease, peripheral vascular disease,
and cerebrovascular disease. The working and result of Plavix is
better than aspirin. Due to this they have high and good market in
all part of the world. By understanding this many manufactures came
to produce Clopidogrel. Now clopidogrel is marketed by the world
largest and global pharmaceutical, Bristol-Myers Squibb and Sanofi-Aventis
under the trade name Plavix.
Sanofi-Aventis is the world's third largest pharmaceutical company
mainly gives importance in researching the new versions of drugs.
They are also mingled with the researches regarding Plavix.
A Canadian generic pharmaceuticals company known as Apotex has the
patent to market and produce the Plavix before 2006. Due to a court
order the patent of Clopidogrel or Plavix is transferred to
Bristol-Myers Squibb and Sanofi-Aventis.
This patent is valid and has a patent protection until November
2011. In about 2007 many small companies are entered in the field of
Plavix production, but the court restricted these small companies
from the manufacturing of Clopidogrel. In 2007 the sales of
Clopidogrel is covered US$5.9 billion and became the world's second
highest selling pharmaceutical. Now Plavix is marketed in nearly 110
countries in different part of the world. The manufactures of Plavix
is mainly concentrated in the United States and also in Europe. In
addition to these countries several pharmaceutical companies are
arise from India and china for producing Plavix at a lower retail
price.
|
|
|
|
|
